home / stock / srrk / srrk quote
Last: | $17.76 |
---|---|
Change Percent: | -11.26% |
Open: | $17.19 |
Close: | $17.76 |
High: | $17.9 |
Low: | $15.27 |
Volume: | 1,749,788 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$17.76 | $17.19 | $17.76 | $17.9 | $15.27 | 1,749,788 | 03-28-2024 |
$15.45 | $15.16 | $15.45 | $15.54 | $15.13 | 602,610 | 03-27-2024 |
$15 | $16.23 | $15 | $16.425 | $14.9015 | 1,045,091 | 03-26-2024 |
$16.01 | $16.18 | $16.01 | $16.935 | $15.73 | 639,938 | 03-25-2024 |
$16.39 | $17.11 | $16.39 | $17.35 | $16.31 | 816,240 | 03-22-2024 |
$17.2 | $16.8 | $17.2 | $17.22 | $15.66 | 2,497,240 | 03-21-2024 |
$16.45 | $14.98 | $16.45 | $16.88 | $14.97 | 2,191,702 | 03-20-2024 |
$15.15 | $12.81 | $15.15 | $15.27 | $12.81 | 1,624,150 | 03-19-2024 |
$13.2 | $14.23 | $13.2 | $14.415 | $13.12 | 873,081 | 03-18-2024 |
$14.45 | $14.72 | $14.45 | $15.13 | $14.3001 | 4,197,408 | 03-15-2024 |
$14.78 | $16.14 | $14.78 | $16.495 | $14.72 | 859,149 | 03-14-2024 |
$16.38 | $16.42 | $16.38 | $16.98 | $16.14 | 599,385 | 03-13-2024 |
$16.61 | $16.22 | $16.61 | $16.765 | $15.88 | 734,458 | 03-12-2024 |
$16.28 | $17.19 | $16.28 | $17.42 | $16.235 | 837,815 | 03-11-2024 |
$16.98 | $16.89 | $16.98 | $17.2499 | $16.21 | 857,945 | 03-08-2024 |
$16.02 | $16.59 | $16.02 | $16.655 | $15.4 | 914,467 | 03-07-2024 |
$16.38 | $16.01 | $16.38 | $16.65 | $16.01 | 821,662 | 03-06-2024 |
$15.82 | $15.72 | $15.82 | $17.04 | $15.38 | 2,037,995 | 03-05-2024 |
$15.36 | $15.99 | $15.36 | $15.99 | $14.7 | 665,867 | 03-04-2024 |
$15.68 | $15.49 | $15.68 | $15.995 | $15.33 | 655,980 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
- Pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy on track to report topline data in 4Q 2024 - Announced FDA clearance of IND application to initiate Phase 2 proof-of-concept trial with apitegromab to treat obesity; expected to commence in mid-2024 - Pres...